Kornimate/medical-research-clean huggingface dataset:
the influence of daily intake of whole grain barley or oats on biomarkers of cardiovascular disease

Conditions: Healthy

Summary: the objectives of this study are the following: 1) to determine the effect of daily consumption of whole grain barley for six week on risk factors of cardiovascular disease compared to a diet low in whole grains, and 2) to compare the effects of daily consumption of whole grain barley to those of whole grain oats for six weeks to determine if the response to these two grains is different.


Eligibility criteria:
inclusion criteria: * men and women between the ages of 25-70 years * body mass index (bmi) ≥ 19 and ≤ 38 * willingness and ability to make scheduled appointments at clinical site as required by study protocol exclusion criteria: * do not regularly consume breakfast or dislike cereal for breakfast * known (self-reported) allergy or adverse reaction to grains (e.g., wheat, gluten, barley) * presence of kidney disease, liver disease, gout, untreated or unstable hypothyroidism, untreated or unstable hyperthyroidism, certain cancers, gastrointestinal disease, pancreatic disease, other metabolic diseases, or malabsorption syndromes * type 2 diabetes requiring the use of oral antidiabetic agents or insulin * fasting triglycerides \> 300 mg/dl * fasting glucose \> 126 mg/dl * use of cholesterol lowering medication * blood pressure \> 180/100 or hypertension treated with calcium channel blockers, direct acting vasodilators, or beta blockers * history of bariatric or certain other surgeries related to weight control * history of major surgery within 3 months of enrollment * smokers or other tobacco users (during 6 months prior to the start of the study) * antibiotic use during the intervention or for 3 months prior to the intervention period * history of eating disorders or other dietary patterns which are not consistent with the dietary intervention (e.g., vegetarians, very low fat diets, high protein diets) * volunteers who have lost 10% of body weight within the last 6 months * unable or unwilling to give informed consent or communicate with study staff * self-report of alcohol or substance abuse within the past 12 months and/or current acute treatment or rehabilitation program for these problems (long-term participation in alcoholics anonymous is not an exclusion) * other medical, psychiatric, or behavioral factors that in the judgment of the principal investigator may interfere with study participation or the ability to follow the intervention protocol

Keywords: barley oats whole grains cardiovascular disease adults not taking lipid-lowering or glucoregulatory medications.
dexmeditomedine as an adjuvant to levobupivacaine in transversus thoracis plane block on the management of post-sternotomy pain in open-heart surgeries

Conditions: Pain, Postoperative

Summary: the study is to assess the efficacy of dexmeditomedine as an adjuvant to the local anaesthetic levobupivacaine in transversus thoracis plane block given bilaterally on the management of post-sternotomy pain.

the patients will fall into one of two groups using an online randomizer. this study is an assessor-blinded interventional controlled study. the first group will recieve transversus thoracis plane block bilaterally where 15 ml of 0.25% levobupivacaine will be given. and the other group shall also undergo a bilateral transversus thoracis plane block with 15 ml 0.25% levobupivacaine and 0.05 ug/kg dexmeditomedine on each side. the primary aim of the study is the 24 hour post-operative morphine consumption.

Eligibility criteria:
inclusion criteria: * adult patients \> 20 years old. * asa ii to iii patients undergoing elective cardiac surgery via a median sternotomy exclusion criteria: * patient's refusal. * known contraindications to regional blocks, including local skin infections,and coagulopathy. * allergies to the local anaesthetics used. * patients undergoing complex cardiac procedures. * patients with severe chronic obstructive pulmonary disease. * patients unable to communicate. * patients with chronic pain. * patients with severe pulmonary hypertension.
repeat antenatal corticosteroids

Conditions: Antenatal Corticosteroids

Summary: this study will review records of women who broke their water early who received a repeat course of antenatal steroids.

antenatal corticosteroids (ancs) administered to a mother at risk of preterm delivery have been shown to decrease morbidity of prematurity if preterm birth occurs. although early animal studies found that many repeated doses led to growth restriction a single repeat dose was found to benefit human neonates without a significant decrease in birth weight. current guidelines recommend two doses of ancs administered 24 hours apart as a single "course." a repeat course of steroids is administered no less than 1-2 weeks after the first course if the mother remains at risk of preterm delivery. however, the main studies supporting the repeat course of ancs excluded women with preterm premature rupture of membranes (pprom). these authors designed exclusion criteria this way because of a theoretical increased risk of chorioamnionitis with administration of a glucocorticoid, which may have immunosuppressant effects. as a result, there is insufficient data to recommend a repeat dose of ancs in women with pprom. one study and its follow up publication did include women with pprom. it did not find an increased incidence of chorioamnionitis between the treatment and the placebo groups, although women with pprom were not analyzed separately. the combination of no increased incidence of chorioamnionitis but no clearly studied populations creates an opportunity for a randomized controlled trial of repeat doses of ancs including only women with pprom.

Eligibility criteria:
inclusion criteria: * pregnant women with preterm premature rupture of membranes exclusion criteria: * women who did not have preterm premature rupture of membranes
impact of sarcopenia using an easy psoas area measurement

Conditions: Sarcopenia

Summary: the purpose of this study is to compare the post-operative course in patients suffering from sarcopenia who had colorectal surgery for cancer. our primary outcome is the comparaison of the length of hospital stay in sarcopenic and non sarcopenic patients.

sarcopenia is the loss of muscle mass that occurs usually with aging, but it may have multiple contributing factors, especially related to chronic diseases such as colorectal cancer. when present, sarcopenia is predictive of poor post-operative course. the identification of sarcopenia needs either the identification of low muscle strength, low muscle quantity/quality, or finally a low physical performance. multiple clinical, biological or radiological tools were proposed. our purpose is to compare the post-operative outcome of sarcopenic and non sarcopenic patients using a simple, available, reproducible and rapid radiological method, which will help the healthcare professionals to rapidly identify high risk patients for possible complicated and long post-operative course allowing them to take appropriate perioperative measures to reduce the risks.

Eligibility criteria:
inclusion criteria: * patient operated on for colectomy or proctectomy with restoration of continuity for colorectal cancer between 1 january 2020 and 31 december 2021 * patient who had a ct scan in the 2 months prior surgery * patient aged 18 years or older exclusion criteria: * patients with inflammatory bowel disease (crohn disease, haemorrhagic rectocolitis) * patients with neuromuscular pathology affecting their mobility * patients who were diagnosed positif to sars cov 2 before or during hospitalisation * patients who refuse the collection of their data

Keywords: sarcopenia colorectal neoplasm colorectal surgery psoas muscles
identifying and overcoming barriers to diabetes management in the elderly: an intervention study

Conditions: Diabetes

Summary: the purpose of this research study is to identify barriers affecting self care in older patients with diabetes and to provide coping strategies for these barriers with help from a care manager (geriatric life specialist) to improve clinical, economical, functional and psychosocial parameters.

this is a study to evaluate whether short term focused intervention by a geriatric diabetes team, with addition of a care manager, to help overcome barriers to diabetes care in older adults will result in improved clinical, functional, and quality of life measures compared to usual care. in addition, we will assess whether the support network formed during intervention by the geriatric diabetes team will empower patients, resulting in long lasting improvement in parameters after intervention is completed. we will also explore whether improved blood glucose control will improve blood circulation in the brain that is compromised in elderly with diabetes.

Eligibility criteria:
inclusion criteria: * age 70 years and older * diagnosis of type 1 or type 2 diabetes * seen at joslin clinic or beth israel deaconess medical center for at least one year * hba1c 8% x 2 in past 6 months without fluctuation of more than 0.5% (i.e. stable poor control) * no major change in medications in past 3 months, e.g. addition of insulin or another hypoglycemic agent exclusion criteria: * patients with terminal diseases, e.g. malignancy with life expectancy of 12 months or less * patients who live more than 25 miles from joslin clinic/ beth israel deaconess medical center * patients who live in an institutional setting, e.g. nursing home, group home, etc * patients who are not able to complete outcome assessments,(e.g. poor vision, diminished mental capacity/severe cognitive decline, unable to speak/read/write english, etc) * patients will be excluded from participation in study aim 3 if they have a history of orthostatic hypotension, tia, or vertebral basilar insufficiency

Keywords: barriers intervention elderly glycemic control
efficacy of denosumab treatment in bisphosphonate unresponsive patients

Conditions: Postmenopausal Osteoporosis

Summary: this study, which was designed as a prospective observational study, was planned to enroll 75 female patients with postmenopausal osteoporosis who had been using bisphosphonates for more than two years and did not respond to treatment. 2 doses of denosumab were administered to the patients every 6 months. bone mineral density of patients were measured with dexa at the beginning and end of the study. a total of 66 patients completed the study. at the end of the study, there was a significant improvement in the femur and lumbar total bone mineral density of the patients compared to the baseline. however, no statistically significant difference was found in terms of the frequency of new fractures.


Eligibility criteria:
inclusion criteria: * being a woman with postmenopausal osteoporosis * being between the ages of 45-85 * using bisphosphonate therapy for at least two years * vertebral and/or femur t score below -2.5 * unresponsive to bisphosphonate therapy * more than 2% decrease in bmd values despite using bisphosphonates and/or * new major fracture development during treatment exclusion criteria: * male gender * being extremely thin (bmi \ 45) * malignancy * severe chronic liver and kidney failure * chronic steroid use * having an active rheumatic disease * having other secondary causes of osteoporosis (primary hyperparathyroidism etc.).
relationship between neurological disability and visual impairment in patients with als or friedreich's ataxia

Conditions: Amyotrophic Lateral Sclerosis

Summary: the aim of this study is to obtain an early biomarker of amyotrophic lateral sclerosis and friedreich's ataxia which allows to diagnose the disease in an initial stage and to follow up the patient with optic coherence tomography, a fast, non-invasive and comfortable method

all patients will be asked about their data and their general medical history, and will be underwent on one hand, a complete neurological examination including the degree of neurological impairment quantified according to the functional rating scale of als (alsfrs-r) or scale for the assessment and rating of ataxia (sara); on the other hand, they will have a complete ophthalmological examination too, including the patient's graduation, pupillary and ocular motility examination, biomicroscopy, goldman tonometry and fundus exam. patients will be performed too a conventional automated humprey perimetry, color test (farnsworth-munsell 28 hue color vision test) and finally an optical coherence tomography (oct) in order to see possible anatomical alterations in both macula and optic nerve. the follow-up of these explorations will be repeated in all cases at 6 months.

Eligibility criteria:
inclusion criteria: * older than 18 years. * best corrected visual acuity more than 0.4 (20/50 snellen = 0.4 logmar = 65 etdrs letters). * refractive defect less than 5 diopters of spherical equivalent and / or cylinder less than 2 diopters. * transparent optical media: opacity of crystalline \<1 according to lens opacities classification system (locs) iii. * open anterior chamber angle assessed by gonioscopy with goldmann lens (grade\> iii). * availability and collaboration to carry out the tests of the exploratory protocol. * acceptance of informed consent. exclusion criteria: * previous intraocular surgeries of less than 6 months of evolution. patients with refractive surgery using the lasik or lasek technique will not be excluded. * physical or mental difficulties to perform reliable and reproducible perimeters. * pathology and / or ocular malformations, angular or optic nerve anomalies. * any retinopathy or maculopathy. * intraocular pressure (iop)\> 21 mmhg. * signal-to-noise ratio in oct less than 5/10. * failure to meet any inclusion criteria. * mental retardation or any other limitation in obtaining informed consent.

Keywords: optical coherence tomography amyotrophic lateral sclerosis
comparison of cardiovascular outcomes of pioglitazone and metformin in type 2 diabetes patients

Conditions: Type 2 Diabetes

Summary: the study aims to see if there is any significant difference in the cardiovascular outcomes in type 2 diabetes patients who are treated with pioglitazone or metformin


Eligibility criteria:
inclusion criteria: 1. newly diagnosed (less than six months since diagnosis and not controlled on dietary modifications) type 2 diabetic patients of both sexes aged 25-60 years. 2. ready to give written informed consent exclusion criteria: 1. presence of ketonuria 2. severe concurrent, infection or illness 3. history of hypersensitivity to any study drug 4. impaired renal function 5. pulmonary insufficiency with hypoxemia 6. severe hepatic disease 7. congestive heart failure 8. history of myocardial infarction or angina(stable/unstable) 9. history of alcohol or drug abuse 10. pregnant or lactating women -
defining a technique for the use of cryogenic catheters for biopsy and ablation for the diagnostic and treatment of pulmonary lesions: an ex-vivo human lung model study.

Conditions: Lung Diseases

Summary: developing a standardized methodology for the use of novel cryogenic catheters for transbronchial cryobiopsy and cryoablation of pulmonary lesions.

surgical lung biopsy (slb) and surgical resection are the current gold standard for both tissue sampling and ablation of pulmonary lesions. albeit the use of minimally invasive surgical techniques (vats), these interventions are frequently associated with complications which include: prolonged air leak, pneumonia, prolonged length of stay in the intensive care unit as well as an increased mortality rate which is influenced by the nature (elective vs non-elective) of the case. to reduce trauma to patients, transbronchial interventions are becoming increasingly popular. however, current techniques have only been demonstrated in humans for lung biopsy and often provide lesser quality specimens than slb. promising results have been achieved using cryotechnology but a standardized technique has yet to be established. to demonstrate the potential for transbronchial interventions using cryo, we aim to develop a standardized technique for transbronchial cryobiopsy and cryoablation of pulmonary lesions using a human ex-vivo model.

Eligibility criteria:
inclusion criteria: * patients undergoing lung transplant surgery exclusion criteria: * organ donor ineligible to donate lungs * healthy individuals

Keywords: lung cryobiopsy cryoablation transbronchial intervention
side effects of q-switched ruby laser for the treatment of lentigines in light and dark skin types

Conditions: Solar Lentigines

Summary: the purpose of this study is a comparison of efficacy and side effects of q-switched ruby laser treatment for solar lentigines in two different skin types ii and iv.

it has been widely accepted that dark colored individuals are prone to develop laser induced side effects especially post inflammatory hyperpigmentation(pih) and it could be a limiting issue in selecting dark colored individuals. we designed this study to evaluate the difference of efficacy and side effects in light and dark skinned individuals.

Eligibility criteria:
inclusion criteria: * solar lentigines * fitzpatrick skin type ii and iv exclusion criteria: * pregnancy * age above 80 * photosensitivity * concern for malignancy * active infection

Keywords: q-switched ruby laser
a novel magnetic needle using iron oxide nanoparticles for the detection of leukemia

Conditions: Leukemia

Summary: the purpose of this study is to determine if the magnetic needle, in combination with magnetic nanoparticles can accurately identify minimal residual disease in leukemia patients.

the ability to reliably detect minimal residual disease (mrd) in leukemia patients allows oncologists to predict patient outcome and to monitor the efficacy of therapy which is critical to improving care. mrd can be used to identify high risk patients who cannot be identified by conventional high risk features, a presence of \< 0.1% mrd has been shown to be one of the best predictors of 5-year remission, with 70% of patients with ≥ 0.1% relapsing. in addition to providing predictions of relapse, mrd has been shown to provide a sensitive measure of early treatment response, an independent predictor of good outcome. while the presence of mrd is indicative of patient outcome, the detection of the presence of mrd provides an opportunity to modify treatment and potentially increase survival. studies are currently underway to use mrd detection in modifying chemotherapeutic treatment and timing of stem cell transplant in leukemia patients. development of a low cost and easily accessible mrd detector has the potential to expand the number of patients for which mrd testing is available. expansion of the patient population is a necessary step to large scale testing of mrd detection as both a predictive factor of patient outcome and as a potential modifier of patient treatment. it is expected that increased mrd testing would lead to improved prediction of patient outcomes and increased sensitivity of testing of treatment response. mrd testing in the general patient population could be used to test treatment response and allow oncologists to modify treatment regiments leading to reduced patient mortality and improved medical outcomes.

Eligibility criteria:
group: leukemia patients inclusion criteria: * suspected diagnosis of leukemia * requiring bone marrow biopsy for standard care exclusion criteria: * unable to consent for entrance into the study group: non-leukemia patients inclusion criteria: * requiring bone marrow biopsy for standard care exclusion criteria: * unable to consent for entrance into the study * leukemia diagnosis

Keywords: leukemia magnetic needle magnetic nanoparticles cd34
study of the genetic and environmental factors of vulnerability in bipolar disorders

Conditions: Bipolar Disorder

Summary: bipolar disorder is a complex, multifactorial disorder with the intervention of genetic vulnerability factors. to help the identification of these genetic factors and to improve genotype-phenotype correlation, the identification of endophenotype through the exploration of vulnerability characteristics in unaffected first degree relatives have been recommended. for this purpose, the investigator include bipolar patients, unaffected first degree relatives and control subjects to perform genetic association studies and subphenotype analyses. in this study the investigator will focus on subgroups defined according to the existence of abnormal circadian rhythm (a major indicator of bipolar vulnerability). lithium is the leading treatment of bipolar disorders but prophylactic lithium response is highly variable and difficult to predict due to lack of biomarkers of response. to explore lithium response variability and to identify biomarkers of response, the investigator characterise lithium response using "alda" scale to conduct pharmacogenetic studies and pharmacokinetic studies of lithium extended release, in the subpopulation of patients treated with lithium. as lithium is a circadian agent, the investigator will also explore the links between lithium response and circadian phenotypes. finally, using li7 magnetic spectroscopy, the investigator will compare lithium brain distribution in a small sample of good and partial responders to lithium.


Eligibility criteria:
inclusion criteria: * patients with bipolar i, ii or not otherwise specified (nos) disorders * euthymic * age \> 18 * affiliated to the french social health care system * somatic state compatible with a blood test * informed consent signed for the study * european exclusion criteria: * patients major protected * patients adopted * geographical origin of grandparents unknown

Keywords: bipolar disorders genetic biomarkers circadian rhythm